Browsing Category

Top Industry News

7096 posts

Lonza Names Siegfried CEO as the Company’s New CEO 
By

By
Lonza has named Wolfgang Wienand, currently CEO of Siegfried Holding AG,  a CDMO of drug substances and drug products, as CEO. Wienand will join Lonza during the summer of 2024.…

Recipharm Divests Mfg Sites and Completes Spinout of Drug Delivery Business
By

By
Recipharm, a CDMO of drug substances and drug products, reports that Blue Wolf Capital Partners, a US-based private equity firm, has committed, subject to regulatory clearances, to acquire seven of its…

Genmab To Acquire ProfoundBio for $1.8 Bn
By

By
Genmab, a Copenhagen, Denmark-based bio/pharmaceutical company, has agreed to acquire ProfoundBio, a Seattle, Washington-based bio/pharmaceutical company, for $1.8 billion.   ProfoundBio is a privately owned clinical-stage biotechnology company developing antibody drug…

Bora Pharmaceuticals Completes $210-M Acquisition of Upsher-Smith
By

By
Bora Pharmaceuticals, a Taipei City, Taiwan-based pharmaceutical company and CDMO of drug products, has completed its acquisition of Upsher-Smith Laboratories, a pharmaceutical company focused on specialty brands and generics, for…

Lonza To Acquire Large-Scale Biologics Mfg Site from Roche for $1.2 Bn 
By

By
Lonza has agreed to acquire a large-scale biologics manufacturing site in Vacaville, California, from Roche’s Genentech for $1.2 billion.  The Vacaville facility currently has a total bioreactor capacity of approximately…

BMS Completes $14-Bn Acquisition of Karuna Therapeutics 
By

By
Bristol Myers Squibb (BMS) has completed its $14-billion acquisition of Karuna Therapeutics, a Boston-based bio/pharmaceutical company specializing in neuroscience-based drugs. The acquisition was first announced in December 2023. The deal…

Gilead Completes $4.3-Bn Acquisition of CymaBay Therapeutics 
By

By
Gilead has completed its $4.3-billion acquisition of CymaBay Therapeutics, a Newark, California-based clinical-stage bio/pharmaceutical company. The deal was announced in February 2024.  CymaBay’s lead candidate is seladelpar, an oral drug…

AstraZeneca To Acquire Fusion Pharmaceuticals & Amolyt Pharma in Combined $3.4-Bn Deals 
By

By
AstraZeneca has agreed to acquire two companies in two separate deals: Fusion Pharmaceuticals, a Hamilton, Ontario, Canada-based clinical-stage bio/pharmaceutical company, in a $2.4-deal billion (includes $2 billion upfront), and Amolyt…

J&J Completes $2-Bn Acquisition of ADC Company Ambrx Biopharma 
By

By
Johnson & Johnson (J&J) has completed its acquisition of Ambrx Biopharma, a La Jolla, California-based bio/pharmaceutical company, for a total equity value of $2.0 billion. The deal was announced in…

Novo Nordisk To Acquire Cardior Therapeutics in $1.1-Bn Deal 
By

By
Novo Nordisk has agreed to acquire Cardior Pharmaceuticals, a Hanover, Germany-based bio/pharmaceutical company, in an EUR 1.025 billion ($1.1 billion) deal. The deal includes an undiclosed upfront payment and additional…